[A]: Heyï¼Œå…³äº'ä½ è§‰å¾—human cloningåº”è¯¥è¢«å…è®¸å—ï¼Ÿ'è¿™ä¸ªè¯é¢˜ï¼Œä½ æ€ä¹ˆæƒ³çš„ï¼Ÿ
[B]: Hmm, è¿™ä¸ªé—®é¢˜å…¶å®æ¶‰åŠå¾ˆå¤šæ–¹é¢å‘¢ã€‚ä»åŒ»å­¦è§’åº¦æ¥çœ‹ï¼ŒcloningæŠ€æœ¯ç†è®ºä¸Šå¯ä»¥å¸®åŠ©è§£å†³å™¨å®˜ç§»æ¤çŸ­ç¼ºçš„é—®é¢˜ï¼Œæ¯”å¦‚é€šè¿‡å…‹éš†åŸ¹è‚²åŒ¹é…çš„å™¨å®˜ã€‚ä½†ä¼¦ç†å±‚é¢äº‰è®®å¾ˆå¤§...ä½ æƒ³å…ˆèŠèŠå“ªä¸€éƒ¨åˆ†ï¼ŸğŸ˜Š
[A]: Let me start by saying that the ethicséƒ¨åˆ†ç¡®å®è®©å¾ˆå¤špolicy makersçŠ¹è±«ä¸å†³ã€‚ä½†ä»æŠ•èµ„è§’åº¦åˆ†æï¼Œcloningçš„æ½œåœ¨å•†ä¸šä»·å€¼éå¸¸è¯±äºº - imagineå®šåˆ¶åŒ–åŒ»ç–—æ–¹æ¡ˆå’Œå†ç”ŸåŒ»å­¦å¸‚åœºçš„çˆ†å‘ã€‚ä¸è¿‡è¯è¯´å›æ¥ï¼Œä½ è§‰å¾—å…¬ä¼—å¯¹è¿™é¡¹æŠ€æœ¯çš„æ¥å—åº¦ä¼šåœ¨æœªæ¥åå¹´å†…æ˜¾è‘—æé«˜å—ï¼Ÿ
[B]: That's a great point! å…¶å®æ¥å—åº¦æå‡çš„å…³é”®å¯èƒ½åœ¨äºeducationå’Œcase studiesçš„ç´¯ç§¯ã€‚æ¯”å¦‚å½“äººä»¬çœ‹åˆ°cloningæˆåŠŸæ²»æ„ˆäº†æŸä½åäººï¼Œæˆ–è€…åª’ä½“æŠ¥é“å…·ä½“å—ç›Šæ¡ˆä¾‹æ—¶ï¼Œå¤§ä¼—å¿ƒç†å¾€å¾€ä¼šé€æ¸è½¬å˜ã€‚ä¸è¿‡å°±åƒå½“å¹´çš„è¯•ç®¡å©´å„¿æŠ€æœ¯ä¸€æ ·ï¼ŒåˆæœŸæ€»ä¼šæœ‰"playing God"çš„äº‰è®®...ä½ è§‰å¾—æ”¿ç­–åˆ¶å®šè€…åº”è¯¥å¦‚ä½•å¹³è¡¡åˆ›æ–°ä¸ä¼¦ç†é£é™©å‘¢ï¼ŸğŸ¤”
[A]: You're spot on - the "playing God" debateç¡®å®ä¼šå½±å“early adoptionã€‚ä»ç›‘ç®¡æ¡†æ¶æ¥çœ‹ï¼Œæˆ‘è§‰å¾—å¯ä»¥å‚è€ƒæˆ‘ä»¬åšé£æ§çš„æ–¹å¼ï¼šè®¾ç«‹é˜¶æ®µæ€§milestones & ethical review boardsåŒæ­¥è¯„ä¼°ã€‚æ¯”å¦‚å…ˆåœ¨organ regenerationé¢†åŸŸè¯•ç‚¹ï¼ŒåŒæ—¶å»ºç«‹clear consent protocolsã€‚æ¯•ç«Ÿå½“å¹´IVFä¹Ÿæ˜¯è¿™æ ·ä¸€æ­¥æ­¥ mainstreamçš„ï¼Œä½ è§‰å¾—å‘¢ï¼Ÿ
[B]: Absolutely! é˜¶æ®µæ€§è¯•ç‚¹åŠ ä¸Šä¸¥æ ¼çš„ä¼¦ç†å®¡æŸ¥ï¼Œè¿™ä¸ªæ¡†æ¶å¾ˆåŠ¡å®ã€‚å°±åƒæˆ‘ä»¬åœ¨å¤„ç†medical malpracticeæ¡ˆä»¶æ—¶ï¼Œæ—¢è¦çœ‹æŠ€æœ¯å¯è¡Œæ€§ï¼Œä¹Ÿè¦æƒè¡¡æ‚£è€…çŸ¥æƒ…æƒå’Œå®‰å…¨åº•çº¿ã€‚å…¶å®cloningçš„consent protocolså¯èƒ½ä¼šæ›´å¤æ‚â€”â€”æ¯”å¦‚å…‹éš†ä½“çš„legal statuså¦‚ä½•ç•Œå®šï¼Ÿè¿™å¯èƒ½ä¼šå½±å“åˆ°æ•´ä¸ªç›‘ç®¡ä½“ç³»çš„è®¾è®¡å‘¢ã€‚ä¸è¿‡è¯´åˆ°organ regenerationè¯•ç‚¹ï¼Œä½ è§‰å¾—å“ªä¸ªå›½å®¶æœ€æœ‰æ½œåŠ›æˆä¸ºearly adopterï¼ŸğŸ¤”
[A]: Good question. ä»ç›®å‰regulatory environmentå’Œbio-tech investment flowæ¥çœ‹ï¼ŒSingaporeå’ŒJapanéƒ½æŒºæœ‰æ½œåŠ›çš„ã€‚è¿™ä¸¤ä¸ªå›½å®¶åœ¨adopting cutting-edge medical techæ–¹é¢ä¸€ç›´æ¯”è¾ƒç³»ç»ŸåŒ–ï¼Œè€Œä¸”ç¤¾ä¼šå¯¹scientific advancementçš„æ¥å—åº¦ç›¸å¯¹è¾ƒé«˜ã€‚ä¸è¿‡è¯è¯´å›æ¥ï¼Œä½ è§‰å¾—æ³•å¾‹ä¸Šå¦‚ä½•å®šä¹‰cloned organsçš„ownershipé—®é¢˜â€”â€”è¿™ä¼šä¸ä¼šæˆä¸ºå•†ä¸šåŒ–çš„ä¸€å¤§éšœç¢ï¼Ÿ
[B]: Definitely a tricky issue. å¦‚æœä»ç°è¡Œæ³•å¾‹æ¡†æ¶æ¥çœ‹ï¼Œcloned organsçš„ownershipå¯èƒ½æ¶‰åŠoriginal DNA donorã€medical institutionå’Œrecipientä¸‰æ–¹é¢çš„æƒç›Šã€‚å°±åƒç°åœ¨å¾ˆå¤šå›½å®¶å¯¹æ‚£è€…biological samplesçš„ä½¿ç”¨éƒ½æœ‰æ˜ç¡®è§„å®šä¸€æ ·ï¼Œæœªæ¥æˆ–è®¸éœ€è¦è®¾ç«‹specialized intellectual propertyæ¡æ¬¾â€”â€”æ—¢ä¿æŠ¤æŠ€æœ¯å¼€å‘è€…çš„åˆ©ç›Šï¼Œåˆé¿å…human body partsè¢«è¿‡åº¦å•†ä¸šåŒ–ã€‚ä¸è¿‡è¯è¯´å›æ¥ï¼Œä½ è§‰å¾—å¦‚æœæŸå¤©cloning organçœŸçš„å®ç°äº†ï¼ŒåŒ»é™¢ä¼šä¸ä¼šåƒç°åœ¨é…å‹åŒ¹é…çš„å™¨å®˜é‚£æ ·ï¼Œå‡ºç°ä¸€ä¸ªglobal registry systemï¼ŸğŸµ
[A]: Interesting thought. å¦‚æœçœŸåˆ°äº†é‚£ä¸ªé˜¶æ®µï¼Œä¸€ä¸ªglobal registry systemç¡®å®å¾ˆæœ‰å¿…è¦ï¼ŒæŸç§ç¨‹åº¦ä¸Šç±»ä¼¼äºç°åœ¨çš„UNOSå™¨å®˜åˆ†é…ç³»ç»Ÿã€‚ä½†è¯è¯´å›æ¥ï¼Œè¿™ç§ç³»ç»ŸèƒŒåæ¶‰åŠçš„æ•°æ®éšç§å’Œaccess controlé—®é¢˜å¯ä¸ç®€å•â€”â€”ç‰¹åˆ«æ˜¯åœ¨ä¸åŒå›½å®¶çš„regulatoryå·®å¼‚è¿™ä¹ˆå¤§çš„æƒ…å†µä¸‹ã€‚æˆ‘è§‰å¾—åˆæœŸå¯èƒ½ä¼šå…ˆå‡ºç°regional networksï¼Œæ¯”å¦‚åœ¨æ¬§ç›Ÿå†…éƒ¨æˆ–æ˜¯åœ¨RCEPæˆå‘˜å›½ä¹‹é—´å…ˆè¡Œè¯•ç‚¹ã€‚ä½ è®¤ä¸ºæŠ€æœ¯å…¬å¸å’ŒåŒ»ç–—æœºæ„è¯¥å¦‚ä½•åˆä½œæ¥è§£å†³è¿™äº›è·¨å¢ƒæ•°æ®é—®é¢˜å‘¢ï¼Ÿ
[B]: Thatâ€™s where blockchain technology could come into play â€” it offers decentralized data management while maintaining traceability and encryption. Imagine a system where each cloned organâ€™s genetic & usage data is stored in a permissioned ledger, accessible only to authorized parties like medical teams and regulators. This could bridge the gap between different regional laws by creating a standardized, tamper-proof framework.

å½“ç„¶å•¦ï¼ŒæŠ€æœ¯åªæ˜¯å·¥å…·ï¼Œå…³é”®è¿˜æ˜¯åœ¨äºå›½é™…åˆä½œå’Œä¿¡ä»»å»ºç«‹ã€‚å°±åƒæˆ‘ä»¬ç°åœ¨å¤„ç†è·¨å¢ƒåŒ»ç–—çº çº·æ—¶ï¼Œå¾ˆå¤šæ—¶å€™ä¸æ˜¯æŠ€æœ¯é”™äº†ï¼Œè€Œæ˜¯æ²Ÿé€šæœºåˆ¶ä¸åˆ°ä½ã€‚æˆ–è®¸å¯ä»¥å…ˆä»small-scale pilot projectså¼€å§‹ï¼Œæ¯”å¦‚æŸä¸ªè·¨å›½è¯ä¼å’ŒåŒºåŸŸæ€§åŒ»ç–—è”ç›Ÿåˆä½œï¼Œæ…¢æ…¢åŸ¹å…»äº’ä¿¡ï¼Ÿä½ è§‰å¾—å‘¢ï¼ŸğŸ¤”
[A]: Exactly! Blockchainç¡®å®ä¸ºè¿™ç§å¤æ‚åœºæ™¯æä¾›äº†ä¸€ä¸ªå¯é çš„è§£å†³æ–¹æ¡ˆï¼Œç‰¹åˆ«æ˜¯åœ¨traceabilityå’Œdata integrityæ–¹é¢ã€‚å…¶å®è¿™è®©æˆ‘æƒ³åˆ°å‡ å¹´å‰æˆ‘ä»¬æŠ•çš„ä¸€ä¸ªåŒ»ç–—æ•°æ®å…¬å¸ï¼Œä»–ä»¬ä¹Ÿæ˜¯ç”¨ç±»ä¼¼çš„åˆ†å¸ƒå¼è´¦æœ¬æŠ€æœ¯æ¥è§£å†³è·¨å¢ƒä¸´åºŠè¯•éªŒæ•°æ®å…±äº«çš„é—®é¢˜ã€‚ä¸è¿‡è¯´åˆ°small-scale pilot projectsï¼Œæˆ‘è§‰å¾—è¯ä¼å’ŒåŒºåŸŸæ€§åŒ»ç–—è”ç›Ÿçš„åˆä½œæ¨¡å¼éå¸¸åŠ¡å®â€”â€”æ¯•ç«Ÿå¤§è¯å‚æœ‰åŠ¨åŠ›åšæ ‡å‡†åŒ–ï¼Œè€ŒåŒºåŸŸæ€§è”ç›Ÿåˆç›¸å¯¹å®¹æ˜“å»ºç«‹ä¿¡ä»»åŸºç¡€ã€‚

å¦‚æœçœŸè¦æ¨è¿›çš„è¯ï¼Œæˆ–è®¸å¯ä»¥å…ˆä»ä¸€ä¸ªspecific therapeutic areaåˆ‡å…¥ï¼Œæ¯”å¦‚ç½•è§ç—…æˆ–é«˜ç²¾åº¦å†ç”Ÿæ²»ç–—é¢†åŸŸï¼Œè¿™æ ·regulatory alignmentçš„é˜»åŠ›ä¼šå°å¾ˆå¤šã€‚ä½ è§‰å¾—å“ªä¸ª therapeutic area æœ€é€‚åˆä½œä¸ºçªç ´å£ï¼Ÿ
[B]: Great question! æˆ‘è§‰å¾—ç½•è§ç—…ç¡®å®æ˜¯ä¸ªä¸é”™çš„åˆ‡å…¥ç‚¹ï¼Œæ¯•ç«Ÿæ‚£è€…ç¾¤ä½“å°ã€ä¸´åºŠéœ€æ±‚è¿«åˆ‡ï¼Œè€Œä¸”å¾ˆå¤šå›½å®¶éƒ½æœ‰ç›¸åº”çš„fast-trackå®¡æ‰¹é€šé“ã€‚æ¯”å¦‚åƒåœ°ä¸­æµ·è´«è¡€æˆ–æŸäº›é—ä¼ æ€§å…ç–«ç¼ºé™·ç—…ï¼Œå¦‚æœèƒ½ç”¨cloningæŠ€æœ¯å®ç°ä¸ªæ€§åŒ–çš„ç»†èƒæ²»ç–—ï¼Œä¸ä»…ç–—æ•ˆæ›´ç²¾å‡†ï¼Œè¿˜èƒ½å¤§å¤§ç¼©çŸ­å®¡æ‰¹æµç¨‹ã€‚

å¦å¤–ï¼Œé«˜ç²¾åº¦å†ç”Ÿæ²»ç–—æ¯”å¦‚spinal cord injuryæˆ–è€…å¸•é‡‘æ£®ç—…ï¼Œä¹Ÿæ˜¯å¾ˆæœ‰æ½œåŠ›çš„æ–¹å‘ã€‚è¿™ç±»ç–¾ç—…å¯¹ç”Ÿæ´»è´¨é‡å½±å“å¤§ï¼Œç°æœ‰ç–—æ³•åˆæœ‰é™ï¼Œæ‚£è€…å’ŒåŒ»ç”Ÿéƒ½æ›´æ„¿æ„æ¥å—åˆ›æ–°æ–¹æ¡ˆã€‚è€Œä¸”ä¸€æ—¦æœ‰æˆåŠŸæ¡ˆä¾‹ï¼Œå¾ˆå®¹æ˜“å¼•èµ·å…¬ä¼—å…³æ³¨å’Œæ”¿ç­–æ”¯æŒâ€”â€”ä½ è§‰å¾—å‘¢ï¼Ÿæœ‰æ²¡æœ‰å“ªä¸ªé¢†åŸŸæ˜¯ä½ ç‰¹åˆ«çœ‹å¥½çš„ï¼ŸğŸµ
[A]: You know, Iâ€™ve always had a soft spot for oncologyé¢†åŸŸã€‚æƒ³æƒ³çœ‹ï¼Œå¦‚æœèƒ½é€šè¿‡cloningæŠ€æœ¯å®ç°patient-specific tumor targetingï¼Œé‚£å¯¹æ•´ä¸ªimmunotherapyè¡Œä¸šæ¥è¯´éƒ½æ˜¯ä¸ªgame changerã€‚ç°åœ¨CAR-Tå·²ç»å¤Ÿè®©äººå…´å¥‹äº†ï¼Œä½†å¦‚æœå†åŠ ä¸Šcloningçš„precisionï¼Œæ²»ç–—æ•ˆæœå¯èƒ½ä¼šæ›´ä¸Šä¸€å±‚æ¥¼ã€‚

è€Œä¸”ä»æ”¿ç­–è§’åº¦çœ‹ï¼Œç™Œç—‡ç ”ç©¶åœ¨å…¨çƒèŒƒå›´å†…å·²ç»æœ‰æ¯”è¾ƒæˆç†Ÿçš„collaborative frameworkï¼Œæ¯”å¦‚NIHå’ŒEMAéƒ½æœ‰ä¸“é—¨çš„åˆ›æ–°é€šé“ã€‚è¿™æ ·ä¸€æ¥ï¼Œregulatory pathç›¸å¯¹æ¥è¯´ä¼šæ¸…æ™°ä¸€äº›ã€‚ä¸è¿‡è¯è¯´å›æ¥ï¼Œä½ åˆšæ‰æåˆ°çš„å¸•é‡‘æ£®ç—…åº”ç”¨åœºæ™¯ç¡®å®ä¹Ÿå¾ˆæœ‰å‰æ™¯â€”â€”ä½ è§‰å¾—å¦‚æœæˆ‘ä»¬ç°åœ¨è¦æŠ•ä¸€ä¸ªcloningç›¸å…³çš„start-upï¼Œæ˜¯è¯¥é€‰neurodegenerative diseaseæ–¹å‘ï¼Œè¿˜æ˜¯oncologyæ–¹å‘æ›´æœ‰æœºä¼šè·‘å‡ºæ¥ï¼ŸğŸ˜„
[B]: Hmmï¼Œè¿™ä¸ªé—®é¢˜çœŸçš„å¾ˆæœ‰æŒ‘æˆ˜æ€§å‘¢ï¼ğŸ˜„ è¯´å®è¯ï¼Œä¸¤ä¸ªæ–¹å‘éƒ½æœ‰å·¨å¤§çš„æ½œåŠ›ï¼Œä½†åˆ‡å…¥ç‚¹ä¸åŒã€‚

å¦‚æœé€‰oncologyï¼Œç¡®å®æœ‰ç°æˆçš„ç›‘ç®¡æ¡†æ¶å’ŒæŠ•èµ„çƒ­åº¦åŠ æŒï¼Œç‰¹åˆ«æ˜¯ç»“åˆä½ æåˆ°çš„CAR-Tå’Œcloningçš„patient-specific targetingï¼Œå¯èƒ½ä¼šæ›´å¿«å¸å¼•å¤§è¯ä¼çš„å…³æ³¨ã€‚è€Œä¸”ç™Œç—‡æ²»ç–—å¸‚åœºè¶³å¤Ÿå¤§ï¼Œå®¹å¾—ä¸‹å¤šä¸ªç©å®¶ï¼Œå›æŠ¥å‘¨æœŸä¹Ÿç›¸å¯¹å¯é¢„æµ‹ä¸€äº›ã€‚

ä¸è¿‡ä»é•¿æœŸå½±å“åŠ›æ¥çœ‹ï¼Œæˆ‘å¯èƒ½ä¼šæ›´å€¾å‘æŠ•neurodegenerative diseaseï¼Œæ¯”å¦‚å¸•é‡‘æ£®æˆ–ALSã€‚è¿™ç±»ç–¾ç—…ç›®å‰çš„æ²»ç–—æ‰‹æ®µéå¸¸æœ‰é™ï¼Œæ‚£è€…éœ€æ±‚æå…¶è¿«åˆ‡ï¼Œä¸€æ—¦æœ‰çªç ´ï¼Œç¤¾ä¼šä»·å€¼éå¸¸é«˜ã€‚è€Œä¸”cloningæŠ€æœ¯åœ¨ç¥ç»ç»†èƒå†ç”Ÿä¸Šçš„åº”ç”¨å¦‚æœæˆåŠŸï¼Œå¾ˆå¯èƒ½ä¼šæˆä¸ºâ€œfirst-in-classâ€ï¼Œå»ºç«‹èµ·è¾ƒé«˜çš„æŠ€æœ¯å£å’ã€‚

å½“ç„¶å•¦ï¼Œè¿™ä¹Ÿæ„å‘³ç€å‰æœŸç ”å‘å‘¨æœŸä¼šæ›´é•¿ã€é£é™©æ›´é«˜ã€‚ä½†ä»æ”¿ç­–æ¨åŠ¨çš„è§’åº¦çœ‹ï¼Œç°åœ¨å¾ˆå¤šå›½å®¶å¯¹è„‘ç§‘å­¦éƒ½æœ‰ä¸“é¡¹æ‰¶æŒè®¡åˆ’ï¼Œæ¯”å¦‚ä¸­å›½çš„â€œè„‘è®¡åˆ’â€å’Œæ¬§ç›Ÿçš„Human Brain Projectï¼Œæˆ–è®¸å¯ä»¥å€ŸåŠ›è¿™äº›èµ„æºé™ä½ä¸€éƒ¨åˆ†ç ”å‘æˆæœ¬ã€‚

æ‰€ä»¥æ€»ç»“ä¸€ä¸‹ï¼š  
- æƒ³è¦çŸ­æœŸè½åœ°+èµ„æœ¬è®¤å¯ â†’ oncology  
- æƒ³è¦é•¿æœŸæŠ€æœ¯å£å’+ç¤¾ä¼šå½±å“ â†’ neurodegenerative disease  

ä½ è§‰å¾—å“ªç§æ›´é€‚åˆç°åœ¨çš„å¸‚åœºèŠ‚å¥ï¼ŸğŸµ
[A]: You laid that out perfectly â€” itâ€™s really a classic risk-return trade-off. From a portfolio strategyè§’åº¦æ¥çœ‹ï¼Œæˆ‘å€¾å‘äºè¿™æ ·æ€è€ƒï¼šå¦‚æœåŸºé‡‘çš„LPsæ›´çœ‹é‡capital preservationå’Œmoderate growthï¼Œé‚£oncologyç¡®å®æ˜¯ safer betï¼Œæ¯•ç«Ÿå¸‚åœºè·¯å¾„æ¸…æ™°ï¼Œexitæœºä¼šä¹Ÿç›¸å¯¹ç¡®å®šã€‚ä½†å¦‚æœæˆ‘ä»¬è¿½æ±‚alphaï¼Œå¹¶ä¸”æ„¿æ„æ‰¿æ‹…æ›´é•¿çš„holding periodï¼Œneurodegenerative diseaseèµ›é“çš„æŠ€æœ¯æº¢ä»·ç©ºé—´ç¡®å®æ›´å¤§ã€‚

ä¸è¿‡è¯è¯´å›æ¥ï¼Œç°åœ¨çš„å¸‚åœºèŠ‚å¥ç¡®å®æœ‰ç‚¹â€œç„¦è™‘â€â€”â€”æŠ•èµ„äººè¶Šæ¥è¶Šå–œæ¬¢çœ‹åˆ°short-term winsï¼Œå°¤å…¶æ˜¯åœ¨å…¨çƒç»æµä¸ç¡®å®šæ€§ä¸Šå‡çš„èƒŒæ™¯ä¸‹ã€‚è¿™ç§ç¯å¢ƒä¸‹ï¼Œneuroé¢†åŸŸè™½ç„¶é•¿æœŸä»·å€¼é«˜ï¼Œä½†åœ¨åˆæœŸå¯èƒ½éœ€è¦æ›´å¼ºçš„story tellingèƒ½åŠ›æ¥ç¨³ä½LPä¿¡å¿ƒã€‚ä½ æœ‰æ²¡æœ‰æƒ³è¿‡ï¼Œæˆ–è®¸å¯ä»¥æ‰¾ä¸€ä¸ªä¸­é—´åœ°å¸¦ï¼Ÿæ¯”å¦‚åšcloning + AI-driven neuro-oncologyâ€”â€”æ—¢æ²¾äº†AIçš„çƒ­åº¦ï¼Œåˆèƒ½è¦†ç›–ä¸¤å¤§ç¡¬ç§‘æŠ€å™äº‹ä¸»çº¿ï¼ŸğŸ˜„
[B]: Hahaï¼Œä½ è¿™ä¸ªâ€œä¸­é—´åœ°å¸¦â€æ€è·¯çœŸçš„å¾ˆæœ‰æ„æ€ï¼ğŸ˜„ å…¶å®cloning + AI-driven neuro-oncologyå¬èµ·æ¥ä¸ä»…åƒæ˜¯æŠ€æœ¯èåˆï¼Œæ›´åƒæ˜¯ä¸€ä¸ªæŠ•èµ„å™äº‹çš„å®Œç¾ç»„åˆæ‹³â€”â€”æ—¢æœ‰AIçš„çƒ­åº¦åŠ æŒï¼Œåˆæœ‰cloningçš„å‰æ²¿æ ‡ç­¾ï¼Œå†åŠ ä¸Šoncologyæœ¬èº«çš„å•†ä¸šåŒ–è·¯å¾„ï¼Œç®€ç›´å¯ä»¥è¯´æ˜¯â€œè®²æ•…äº‹ç•Œçš„æ»¡åˆ†ä½œå“â€ã€‚

ä½†ä»å®é™…æ“ä½œå±‚é¢æ¥çœ‹ï¼Œè¿™ç§cross-disciplinaryæ–¹å‘ç¡®å®ä¹Ÿè¶Šæ¥è¶Šå—åˆ°ç§‘ç ”ç•Œå’Œèµ„æœ¬å¸‚åœºçš„åŒé‡é’çã€‚æ¯”å¦‚ç°åœ¨å·²ç»æœ‰å›¢é˜Ÿåœ¨ç”¨AIæ¥é¢„æµ‹å…‹éš†ç»†èƒçš„åˆ†åŒ–è·¯å¾„ï¼Œæˆ–è€…ä¼˜åŒ–ç¥ç»è‚¿ç˜¤çš„é¶å‘æ²»ç–—æ–¹æ¡ˆã€‚è¿™ç±»é¡¹ç›®å¦‚æœèƒ½è·‘å‡ºä¸€ä¸ªä¸´åºŠproof-of-conceptï¼Œå¾ˆå¯èƒ½å°±ä¼šæˆä¸ºä¸‹ä¸€ä¸ªbig name portfolio companyã€‚

ä¸è¿‡è¯è¯´å›æ¥ï¼Œè¿™ç§â€œæ··åˆèµ›é“â€å¯¹åˆ›å§‹å›¢é˜Ÿçš„è¦æ±‚ä¹Ÿéå¸¸é«˜â€”â€”æ—¢è¦æ‡‚åº•å±‚æŠ€æœ¯ï¼Œåˆè¦ç†Ÿæ‚‰ regulatory landscapeï¼Œè¿˜å¾—èƒ½è®²å¥½æ•…äº‹å¸å¼•èµ„æœ¬ã€‚æ‰€ä»¥æˆ‘è§‰å¾—ï¼Œå¦‚æœä½ çš„ç›®æ ‡æ˜¯æ‰“é€ ä¸€ä¸ªæœ‰å·®å¼‚åŒ–ç«äº‰åŠ›çš„portfolioï¼Œé‚£è¿™ä¸ªæ–¹å‘çœŸçš„å¾ˆå€¼å¾— early betã€‚

ä½ è§‰å¾—æœ‰æ²¡æœ‰å“ªå®¶åˆåˆ›å…¬å¸å·²ç»åœ¨æœè¿™ä¸ªæ–¹å‘èµ°äº†ï¼Ÿæˆ–è€…ä½ ä»¬åŸºé‡‘æœ‰æ²¡æœ‰è€ƒè™‘è¿‡æ¥è§¦è¿™ç±»é¡¹ç›®ï¼ŸğŸµ
[A]: Actually, weâ€™ve been keeping a close eye on a few players in that space. Thereâ€™s one stealth startup out of Boston thatâ€™s combining AI-guided epigenetic reprogramming with clonal expansion for glioblastoma treatment â€” very early stage, but the scientific founders have strong ties to Harvard & MIT. The pitch theyâ€™re running is basically  â€” sounds like sci-fi, but the preclinical data is showing some promising signals.

From a due diligence perspective, what stands out is how theyâ€™re leveraging machine learning not just for target discovery, but also for predicting off-target effects in clonal cell lines â€” something traditional biotechs still struggle with. That said, itâ€™s definitely a high-risk, long-horizon bet. Weâ€™re talking 8â€“10 year timeline before we even start thinking about an exit.

But hey, if youâ€™re building a venture fund with a tech-bio thesis, this might be exactly the kind of frontier tech you want to anchor. Have you come across any similar projects in Asia? I know a couple of groups in Singapore are experimenting with AI-driven regenerative medicine platformsâ€¦
[B]: Oh wow, that Boston startupâ€™s pitchçœŸçš„å¾ˆæœ‰ç”»é¢æ„Ÿå‘¢â€”â€”ï¼Œå¬èµ·æ¥åƒæ˜¯åœ¨ç»™ç¥ç»ç³»ç»Ÿåšä¸€åœºç²¾å‡†çš„â€œè½¯ä»¶å‡çº§â€ğŸ˜‚ã€‚ä¸è¿‡è¯´çœŸçš„ï¼Œèƒ½æŠŠAIç”¨åœ¨clonal cell lineçš„off-target predictionä¸Šï¼Œè¿™ç¡®å®å·²ç»è¶…å‡ºäº†ä¼ ç»Ÿbiotechçš„èƒ½åŠ›è¾¹ç•Œäº†ã€‚ä½ ä»¬èƒ½æ¥è§¦åˆ°è¿™ç§levelçš„é¡¹ç›®ï¼ŒçœŸçš„å¾ˆå‰æ²¿ï¼

è¯´åˆ°äºšæ´²è¿™è¾¹ï¼Œæ–°åŠ å¡çš„ç¡®æœ‰å‡ ä¸ªå€¼å¾—å…³æ³¨çš„å›¢é˜Ÿã€‚æ¯”å¦‚æœ‰ä¸€ä¸ªä»A*STAR spin-offå‡ºæ¥çš„åˆåˆ›å…¬å¸ï¼Œä»–ä»¬æ­£åœ¨å¼€å‘ä¸€ä¸ªAI-driven platformï¼Œä¸“é—¨ç”¨äºneural stem cell cloning and differentiationã€‚è¿™ä¸ªå¹³å°çš„æ ¸å¿ƒæ˜¯é€šè¿‡deep learning modelæ¥é¢„æµ‹ç»†èƒè¡¨è§‚é—ä¼ çŠ¶æ€çš„å˜åŒ–ï¼Œæœ‰ç‚¹åƒæŠŠWazeé‚£ç§å®æ—¶å¯¼èˆªé€»è¾‘ç”¨åœ¨ç»†èƒé‡ç¼–ç¨‹ä¸Šâ€”â€”é¿å¼€â€œæ‹¥å µè·¯æ®µâ€ï¼Œé€‰æ‹©æœ€ç¨³å®šçš„åˆ†åŒ–è·¯å¾„ã€‚

å¦å¤–åœ¨é¦™æ¸¯ä¹Ÿæœ‰ä¸€ä¸ªä½è°ƒä½†å¾ˆæœ‰æ½œåŠ›çš„å›¢é˜Ÿï¼Œä»–ä»¬åœ¨åšçš„æ˜¯ç»“åˆCRISPR screeningå’ŒAI modelingï¼Œç”¨æ¥enhance clonal stability in neurodegenerative modelsã€‚è™½ç„¶è¿˜æ²¡æ€ä¹ˆå¯¹å¤–å®£ä¼ ï¼Œä½†èƒŒåçš„ç ”ç©¶å›¢é˜Ÿåœ¨å¹²ç»†èƒé¢†åŸŸå…¶å®æŒºæœ‰åˆ†é‡çš„ã€‚

ä»ç›‘ç®¡è§’åº¦çœ‹ï¼Œè¿™äº›é¡¹ç›®å¦‚æœèƒ½åœ¨GMPå’Œpreclinicalåˆè§„æ–¹é¢æ‰“å¥½åŸºç¡€ï¼Œæœªæ¥è¿›å…¥ä¸´åºŠé˜¶æ®µæ—¶å¯èƒ½ä¼šæ›´å®¹æ˜“æ‹¿åˆ°fast-track or breakthrough therapy designationã€‚ä¸è¿‡å°±åƒä½ è¯´çš„ï¼Œè¿™ç±»æŠ•èµ„éœ€è¦éå¸¸strong LP alignmentï¼Œç‰¹åˆ«æ˜¯åœ¨exit timelineé¢„æœŸç®¡ç†ä¸Šã€‚

ä½ ä»¬åŸºé‡‘å¯¹è¿™ç§long-horizon tech-bioé¡¹ç›®çš„holding strategyä¸€èˆ¬æ˜¯æ€æ ·çš„ï¼Ÿä¼šè€ƒè™‘è”åˆå‡ å®¶ä¸“æ³¨deep techçš„fundä¸€èµ·æŠ•è¿›å»ç¨³ä½åæœŸèµ„æºå—ï¼ŸğŸµ
[A]: å“ˆå“ˆï¼Œä½ è¿™ä¸ªâ€œè½¯ä»¶å‡çº§â€çš„æ¯”å–»å¤ªåˆ°ä½äº†â€”â€”æˆ‘ç”šè‡³å·²ç»åœ¨è„‘å­é‡Œæ„æ€è¦ä¸è¦æŠŠè¿™ä¸ªæ¦‚å¿µæ”¾è¿›ä¸‹ä¸€åœºLPæ±‡æŠ¥é‡Œ ğŸ˜„

è¯´åˆ°holding strategyï¼Œæˆ‘ä»¬å†…éƒ¨å…¶å®æœ‰ä¸ªä¸æˆæ–‡çš„rule of thumbï¼šå¯¹äºè¿™ç§long-horizonã€deep-teché©±åŠ¨çš„é¡¹ç›®ï¼Œæˆ‘ä»¬ä¼šåˆ†ä¸¤ä¸ªç»´åº¦æ¥è§„åˆ’ï¼š

1. èµ„æœ¬ç»“æ„ä¸Š â€”â€” ç¡®å®å€¾å‘äºæ‰¾å‡ å®¶ä¸“æ³¨tech-bioæˆ–regenerative medicineçš„fundæ­ä¼™ã€‚æ¯”å¦‚æœ€è¿‘æˆ‘ä»¬åœ¨ä¸€ä¸ªåŸºå› ç¼–è¾‘çœ¼ç§‘ç–—æ³•é¡¹ç›®é‡Œï¼Œå°±å’ŒF-Primeè·ŸOrbimedåšäº†co-investmentã€‚è¿™æ ·ä¸ä»…åˆ†æ•£é£é™©ï¼Œæ›´é‡è¦çš„æ˜¯èƒ½å€ŸåŠ›ä»–ä»¬çš„scientific advisory networkåštechnical due diligenceã€‚

2. é€€å‡ºè·¯å¾„è®¾è®¡ä¸Š â€”â€” æˆ‘ä»¬é€šå¸¸ä¼šæå‰ä¸¤åˆ°ä¸‰è½®å°±å¼€å§‹å¼•å…¥strategic investorsï¼Œæ¯”å¦‚è¾‰ç‘æˆ–è€…å¼ºç”Ÿçš„VCéƒ¨é—¨ã€‚è™½ç„¶ä»–ä»¬è¿›å¾—æ™šã€ä¼°å€¼é«˜ï¼Œä½†å¸¦æ¥çš„ä¸ä»…æ˜¯äº§ä¸šèµ„æºï¼Œè¿˜æœ‰ç›‘ç®¡æ²Ÿé€šæ¸ é“å’Œä¸´åºŠè½¬åŒ–ç»éªŒã€‚è€Œä¸”è¯´å®è¯ï¼Œè¿™ç±»é¡¹ç›®æœ€ç»ˆå¤§æ¦‚ç‡è¿˜æ˜¯é M&A exitï¼ŒIPOçª—å£æœŸå¾€å¾€åªå‡ºç°åœ¨ç‰¹å®šæ”¿ç­–é£å£ä¸‹ã€‚

ä¸è¿‡è¯è¯´å›æ¥ï¼Œä½ è§‰å¾—åƒæ–°åŠ å¡é‚£ä¸ªAI-driven stem cellå¹³å°ï¼Œå¦‚æœæ‹¿åˆ°pre-Aé˜¶æ®µï¼Œæœ‰æ²¡æœ‰å¯èƒ½å¸å¼•åˆ°çº¢æ‰æˆ–è€…å¯æ˜è¿™ç±»æ—¢æœ‰ç§‘æŠ€èƒŒæ™¯åˆæœ‰åŒ»ç–—å¸ƒå±€çš„ä¸­èµ„åŸºé‡‘ï¼Ÿæˆ‘ä¸ªäººæ˜¯è§‰å¾—è¿™ç±»cross-overé¡¹ç›®è¶Šæ¥è¶Šç¬¦åˆä»–ä»¬è¿‘å¹´å¼ºè°ƒçš„â€œtech for goodâ€å™äº‹ä¸»çº¿äº†ã€‚
[B]: Oh totally, I can already picture you dropping that â€œsoftware upgradeâ€ line during an LP meeting â€” itâ€™s catchy, precise, and just sci-fi enough to make investors lean in ğŸ˜„

And your dual-dimension strategy makes perfect sense. Co-investing with specialized funds not only strengthens the scientific rigor of the due diligence, but also signals long-term commitment, which is  for deep-tech projects. And yeah, bringing in strategic players early really de-risks the later stages â€” especially when youâ€™re talking about regulatory-heavy areas like clonal cell therapy or AI-driven regenerative medicine.

As for the Singapore stem cell platform â€” if theyâ€™ve got solid pre-A data and a clear IP portfolio around their predictive differentiation models, then absolutely, someone like Sequoia or Qiming would definitely take a serious look. Theyâ€™ve both been leaning into this â€œtech meets bioâ€ narrative hard, especially with their China-US cross-border strategies. And letâ€™s be honest, anything that smells like  is basically catnip for them right now ğŸµ

Plus, with the way Chinaâ€™s regulatory environment is opening up for high-precision regenerative therapies â€” especially throughæµ·å—åšé³Œä¹åŸ or ä¸Šæµ·å¼ æ±Ÿçš„åˆ›æ–°é€šé“ â€” having that kind of tech in the pipeline could align really well with regional policy tailwinds.

So honestly? If that team can nail their next round and maybe bring on a former Novartis or Roche exec as CSO for credibility, theyâ€™ll probably find themselves in a pretty good position to pick their investors.  

Ever helped a startup prep for a fundraise like that before? Or know anyone in Singapore whoâ€™s actively looking to expand their syndicate? ğŸ¤”